RQ Biotechnology is focused on developing innovative medicines utilizing potent broad-spectrum monoclonal antibodies (mAbs) to provide immediate and long-lasting protection against viral infections, particularly for vulnerable populations at risk of severe disease or death. The company recognizes that traditional vaccines do not adequately protect certain groups, such as immunocompromised individuals, the elderly, and newborns, who are particularly susceptible to severe outcomes from viral infections. RQ Biotechnology aims to address these unmet medical needs by leveraging its expertise in monoclonal antibody research and development, which is crucial for reducing morbidity and mortality associated with viral diseases.

The company's scientific approach involves a multi-faceted strategy to enhance the efficacy of monoclonal antibodies. This includes immunization with stabilized virus receptor binding proteins to target vulnerable virus proteins, identifying resilient natural human antibodies through advanced screening techniques, and utilizing in vitro neutralization assays to predict in vivo potency. By focusing on the evolution of viruses and the immune response, RQ Biotechnology aims to discover and manufacture highly potent antibodies that can provide immediate protection against infections, thereby limiting disease severity and improving health outcomes for at-risk populations.

United Kingdom

RQ Biotechnology is making instant immunity a reality for vulnerable people. As the leading passive immunization discovery company, we partner with pharmaceutical companies to develop our antibodies into protect against infectious diseases where vaccines cannot. RQ Bio is dedicated to developing medicines based on potent broad-spectrum mAbs to provide instant and long-lasting protection for vulnerable people at risk of severe disease or death from current and future viral infections.

RQ Biotechnology

Company Details